<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Programmed <z:hpo ids='HP_0011420'>death</z:hpo> 1 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1) protein, a T-cell coinhibitory receptor, and one of its ligands, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-L1, play a pivotal role in the ability of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells to evade the host's immune system </plain></SENT>
<SENT sid="1" pm="."><plain>Blockade of interactions between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1 and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-L1 enhances immune function in vitro and mediates antitumor activity in preclinical models </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: In this multicenter phase 1 trial, we administered intravenous anti-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-L1 antibody (at escalating doses ranging from 0.3 to 10 mg per kilogram of body weight) to patients with selected <z:e sem="disease" ids="C0877373" disease_type="Neoplastic Process" abbrv="">advanced cancers</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Anti-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-L1 antibody was administered every 14 days in 6-week cycles for up to 16 cycles or until the patient had a complete response or confirmed disease progression </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: As of February 24, 2012, a total of 207 patients--75 with <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small-cell lung cancer</z:e>, 55 with <z:hpo ids='HP_0002861'>melanoma</z:hpo>, 18 with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, 17 with <z:e sem="disease" ids="C0007134" disease_type="Neoplastic Process" abbrv="">renal-cell cancer</z:e>, 17 with <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e>, 14 with <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo>, 7 with <z:hpo ids='HP_0012126'>gastric cancer</z:hpo>, and 4 with <z:hpo ids='HP_0003002'>breast cancer</z:hpo>--had received anti-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-L1 antibody </plain></SENT>
<SENT sid="5" pm="."><plain>The median duration of therapy was 12 weeks (range, 2 to 111) </plain></SENT>
<SENT sid="6" pm="."><plain>Grade 3 or 4 toxic effects that investigators considered to be related to treatment occurred in 9% of patients </plain></SENT>
<SENT sid="7" pm="."><plain>Among patients with a response that could be evaluated, an objective response (a complete or partial response) was observed in 9 of 52 patients with <z:hpo ids='HP_0002861'>melanoma</z:hpo>, 2 of 17 with <z:e sem="disease" ids="C0007134" disease_type="Neoplastic Process" abbrv="">renal-cell cancer</z:e>, 5 of 49 with <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small-cell lung cancer</z:e>, and 1 of 17 with <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Responses lasted for 1 year or more in 8 of 16 patients with at least 1 year of follow-up </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Antibody-mediated blockade of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-L1 induced durable <z:mp ids='MP_0010537'>tumor regression</z:mp> (objective response rate of 6 to 17%) and prolonged stabilization of disease (rates of 12 to 41% at 24 weeks) in patients with <z:e sem="disease" ids="C0877373" disease_type="Neoplastic Process" abbrv="">advanced cancers</z:e>, including <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small-cell lung cancer</z:e>, <z:hpo ids='HP_0002861'>melanoma</z:hpo>, and <z:e sem="disease" ids="C0007134" disease_type="Neoplastic Process" abbrv="">renal-cell cancer</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>(Funded by Bristol-Myers Squibb and others; ClinicalTrials.gov number, NCT00729664.) </plain></SENT>
</text></document>